Are maternal serum subfatin levels altered in women with one abnormal glucose tolerance test value?


Journal

Revista da Associacao Medica Brasileira (1992)
ISSN: 1806-9282
Titre abrégé: Rev Assoc Med Bras (1992)
Pays: Brazil
ID NLM: 9308586

Informations de publication

Date de publication:
2024
Historique:
received: 07 05 2024
accepted: 20 05 2024
medline: 21 8 2024
pubmed: 21 8 2024
entrez: 21 8 2024
Statut: epublish

Résumé

Subfatin, a newly discovered adipokine, plays a pivotal role in the regulation of glucose metabolism. The relationship between gestational diabetes mellitus and maternal dyslipidemia is well-documented. This study aims to assess serum subfatin levels and the triglyceride/high-density lipoprotein cholesterol ratio in women with one abnormal glucose tolerance test value and those with gestational diabetes mellitus. In this case-control study, 105 pregnant women were categorized into three groups: women with normal 3-h oral glucose tolerance test results (n=35), women with one abnormal 3-h oral glucose tolerance test result (n=35), and women diagnosed with gestational diabetes mellitus (n=35). Serum subfatin levels were measured using human enzyme-linked immunosorbent assay kits. Serum subfatin levels were significantly lower in the gestational diabetes mellitus group (0.94±0.15 ng/mL) compared to the normal oral glucose tolerance test group (1.48±0.55 ng/mL) and the group with one abnormal oral glucose tolerance test result (1.50±0.59 ng/mL). The triglyceride/high-density lipoprotein cholesterol ratio was also lower in the healthy control group than in the gestational diabetes mellitus and one abnormal oral glucose tolerance test result groups. Serum subfatin levels in women with one abnormal abnormal glucose tolerance test value are compared to those in the control group, while the triglyceride/high-density lipoprotein cholesterol ratio is significantly altered in women with one abnormal abnormal glucose tolerance test value when compared to the control group.

Sections du résumé

BACKGROUND BACKGROUND
Subfatin, a newly discovered adipokine, plays a pivotal role in the regulation of glucose metabolism. The relationship between gestational diabetes mellitus and maternal dyslipidemia is well-documented.
AIMS OBJECTIVE
This study aims to assess serum subfatin levels and the triglyceride/high-density lipoprotein cholesterol ratio in women with one abnormal glucose tolerance test value and those with gestational diabetes mellitus.
METHODS METHODS
In this case-control study, 105 pregnant women were categorized into three groups: women with normal 3-h oral glucose tolerance test results (n=35), women with one abnormal 3-h oral glucose tolerance test result (n=35), and women diagnosed with gestational diabetes mellitus (n=35). Serum subfatin levels were measured using human enzyme-linked immunosorbent assay kits.
RESULTS RESULTS
Serum subfatin levels were significantly lower in the gestational diabetes mellitus group (0.94±0.15 ng/mL) compared to the normal oral glucose tolerance test group (1.48±0.55 ng/mL) and the group with one abnormal oral glucose tolerance test result (1.50±0.59 ng/mL). The triglyceride/high-density lipoprotein cholesterol ratio was also lower in the healthy control group than in the gestational diabetes mellitus and one abnormal oral glucose tolerance test result groups.
CONCLUSION CONCLUSIONS
Serum subfatin levels in women with one abnormal abnormal glucose tolerance test value are compared to those in the control group, while the triglyceride/high-density lipoprotein cholesterol ratio is significantly altered in women with one abnormal abnormal glucose tolerance test value when compared to the control group.

Identifiants

pubmed: 39166669
pii: S0104-42302024000800600
doi: 10.1590/1806-9282.20231111
pii:
doi:

Substances chimiques

Triglycerides 0
Cholesterol, HDL 0
Blood Glucose 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e20231111

Auteurs

Yıldız Akdas Reis (YA)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Fahri Burcin Firatligil (FB)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Alperen Aksan (A)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Caner Kose (C)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Harun Egemen Tolunay (HE)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Yaprak Ustun (Y)

University of Health Sciences Turkey, Ankara Etlik Zubeyde Hanım Women's Health and Research Center Turkey, Department of Obstetrics and Gynecology - Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH